PC786

DRUG2 trials

Sponsors

Pulmocide Ltd

Conditions

Respiratory Syncytial Virus Infections

Phase 1

A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

CompletedNCT03382431

Pulmocide LtdRespiratory Syncytial Virus Infections

Start: 2017-11-14End: 2018-05-09Updated: 2018-05-16

Phase 2

Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

TerminatedNCT03715023

Pulmocide LtdRespiratory Syncytial Virus Infections

Start: 2018-11-05End: 2019-05-01Updated: 2019-06-12

Related Papers

Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study

The Journal of Infectious Diseases2020-11-1344 citations